Nature Communications (Mar 2024)

Enzymatic conversion of human blood group A kidneys to universal blood group O

  • Serena MacMillan,
  • Sarah A. Hosgood,
  • Léonie Walker-Panse,
  • Peter Rahfeld,
  • Spence S. Macdonald,
  • Jayachandran N. Kizhakkedathu,
  • Stephen G. Withers,
  • Michael L. Nicholson

DOI
https://doi.org/10.1038/s41467-024-47131-9
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 14

Abstract

Read online

Abstract ABO blood group compatibility restrictions present the first barrier to donor-recipient matching in kidney transplantation. Here, we present the use of two enzymes, FpGalNAc deacetylase and FpGalactosaminidase, from the bacterium Flavonifractor plautii to enzymatically convert blood group A antigens from the renal vasculature of human kidneys to ‘universal’ O-type. Using normothermic machine perfusion (NMP) and hypothermic machine perfusion (HMP) strategies, we demonstrate blood group A antigen loss of approximately 80% in as little as 2 h NMP and HMP. Furthermore, we show that treated kidneys do not bind circulating anti-A antibodies in an ex vivo model of ABO-incompatible transplantation and do not activate the classical complement pathway. This strategy presents a solution to the donor organ shortage crisis with the potential for direct clinical translation to reduce waiting times for patients with end stage renal disease.